CCM2L

CCM2L is an endothelial adaptor protein that functions within the Heg-CCM pathway to regulate cardiovascular growth and vascular junction signaling (PMID:26540726, PMID:33657857). It binds CCM1 in a complex that also engages the kinase MEKK3 (Map3k3), and CCM2L (like its paralog CCM2) interferes with MEKK3 activation, blocking phosphorylation of the downstream substrate MEK5; epistasis in zebrafish, where mekk3 silencing rescues ccm2l morphant phenotypes, confirms this suppression operates in vivo (PMID:26540726). Deletion mapping defined the CCM1 regions mediating its binding to CCM2L, and ccm2 overexpression partially rescues ccm2l loss, indicating the two paralogs act on a shared CCM1-anchored module while CCM2L competitively opposes CCM2-mediated stabilizing signals during active cardiovascular growth (PMID:22898778, PMID:23328253). Loss of CCM2L produces dilated atrium and inflow tract defects, reduces endocardial growth factor expression, and aggravates cerebral cavernous malformation through Map3k3-KLF signaling (PMID:22898778, PMID:23328253, PMID:33657857). Compound heterozygous loss-of-function variants in CCM2L were identified in a fetus with Tetralogy of Fallot, with a minigene assay confirming exon 8 skipping and premature termination (PMID:40521769).

1. 2012 Medium

   Established CCM2L as an endothelial-selective, growth-phase-restricted regulator that competitively antagonizes CCM2 stabilizing signals, defining it as a functional counterpart rather than redundant paralog.

   Evidence Biochemical competition assay plus in vivo loss-of-function in developing mice with endocardial growth factor and tumor/wound-healing readouts

   PMID:22898778

   Open questions at the time

   • Molecular basis of competition with CCM2 not resolved at structural level
   • Direct kinase target not yet identified in this study
   • Single-lab phenotypic characterization
2. 2013 High

   Mapped the physical architecture of the CCM1-CCM2L interaction and placed CCM2L genetically within the Heg-CCM pathway via rescue, answering whether CCM2L shares the CCM1 binding interface used by CCM2 and Heg.

   Evidence Co-IP with deletion/mutational mapping; zebrafish ccm2l morpholino knockdown with ccm2 overexpression rescue

   PMID:23328253

   Open questions at the time

   • Did not define the downstream effector of the CCM1-CCM2L complex
   • Cardiac phenotype mechanism beyond inflow tract defects unresolved
3. 2015 High

   Identified MEKK3 as the kinase target of the CCM2L-CCM1 complex and showed CCM2L suppresses MEKK3-driven MEK5 phosphorylation, providing the molecular mechanism linking the adaptor to a signaling cascade.

   Evidence In vitro binding and kinase (MEK5 phosphorylation) assays; zebrafish genetic epistasis (mekk3 silencing rescues ccm2l morphants)

   PMID:26540726

   Open questions at the time

   • Stoichiometry and structure of the CCM1-CCM2L-MEKK3 complex unresolved
   • Quantitative contribution of CCM2L versus CCM2 to MEKK3 suppression not separated
4. 2021 Medium

   Extended the MEKK3 axis to a transcriptional output by linking CCM2L loss to KLF signaling in cerebral cavernous malformation, connecting adaptor function to disease pathology.

   Evidence CCM2L deletion model with Map3k3-KLF pathway readout

   PMID:33657857

   Open questions at the time

   • Limited methodological detail in source
   • Which KLF factors mediate the phenotype not delineated
   • Single lab
5. 2021 Medium

   Tested whether endothelial CCM2L gain-of-function could drive cardiac regeneration, establishing that CCM2L overexpression alone is insufficient to promote cardiomyocyte proliferation or repair.

   Evidence Endothelial-specific Ccm2l gain-of-function transgenic mouse, LAD ligation injury, cardiomyocyte proliferation readout

   PMID:34046845

   Open questions at the time

   • Negative result; does not exclude effects in other contexts or doses
   • Single method, single lab
6. 2025 Medium

   Provided the first human genetic evidence linking CCM2L loss-of-function to congenital heart disease, connecting the developmental role to clinical pathology.

   Evidence Whole exome and Sanger sequencing of a Tetralogy of Fallot fetus; minigene splicing assay confirming exon 8 skipping

   PMID:40521769

   Open questions at the time

   • Single case report
   • No functional pathway follow-up beyond splice consequence
   • Causality not established by family segregation or model

• How CCM2L balances against CCM2 to set the threshold between vascular junction destabilization and stabilization, and whether its human variants act through the MEKK3-KLF axis, remain open.
• No structural model of the CCM1-CCM2L-MEKK3 complex
• Mechanistic link between human CCM2L variants and MEKK3-KLF signaling untested
• Quantitative competition with CCM2 not defined